Key result
Tianhuang Formula (60 or 120 mg/kg daily for 10 weeks) ameliorated lipid profile and attenuated liver steatosis in T2DM mice through CRLS1-ATF3/ChREBP pathway activation.
Why the study?
Tianhuang Formula has been shown to alleviate dyslipidemia, but whether it can improve NAFLD in type 2 diabetic mice and its mechanism remained to be confirmed.
Population
Type 2 diabetic mice induced by HFD/streptomycin (STZ)
Comparison
Tianhuang Formula (60 mg/kg vs 120 mg/kg once daily)
Design
Preclinical animal study
Follow-up
10 weeks
Authors
Loading...
THF effects in diabetic mouse NAFLD remain preclinical; leaves open any human therapeutic role pending trials.
Tianhuang Formula ameliorates lipid profiles and liver steatosis in a mouse model of type 2 diabetes via the CRLS1-ATF3/ChREBP pathway.
Han et al. (2023) studied Non-alcoholic fatty liver diseases (NAFLD) in type 2 diabetes. Tianhuang Formula (THF) was evaluated. Tianhuang Formula (60 or 120 mg/kg daily for 10 weeks) ameliorated lipid profile and attenuated liver steatosis in T2DM mice through CRLS1-ATF3/ChREBP pathway activation.